Drug Profile

ABP 200

Alternative Names: ABP-200

Latest Information Update: 28 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MedImmune
Developer AbMed; AstraZeneca
Class Antineoplastics; Bispecific antibodies
Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)
02 Aug 2018 Preclinical trials in Solid tumours in USA (IV)
31 Mar 2018 AbMed and MedImmune have patent protection for ABP 200 in USA, Australia, Canada, China, Europe and Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com